How is Darzalex administered?
Darzalex™ (daratumumab, Janssen/Genmab) is given as an intravenous (IV) infusion into a vein. It is typically given at a dose of 16 mg/kg of body weight and is administered weekly during Weeks 1 through 8, every two weeks during Weeks 9 through 24, and then every 4 weeks until disease progression.
Before receiving Darzalex, patients receive premedication with antihistamines, fever-reducing agents, and steroids to reduce the risk of infusion reactions. Following the infusion of Darzalex, patients also receive a steroid to reduce the risk of delayed infusion reactions.
Patients receiving Darzalex also receive medication to prevent shingles, a viral infection that causes a painful rash and is due to a reactivation of the virus that causes chickenpox (herpes zoster virus).